An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
Accompanied a study order, see H5596
Email me when S 2035 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track S 2035. By continuing you agree to the Terms and Privacy Policy.
Summary
The Senate bill seeks to remove the state tax deduction that pharmaceutical firms currently claim for advertising directly to consumers. It would affect drug manufacturers and could increase state tax revenue while reducing incentives for aggressive consumer‑focused marketing.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about S 2035
3 free questions a day, no accountHearings
- Advertising & Economic DevelopmentJoint Committee on Revenue · Oct 28, 2025
History
- Reporting date extended to Thursday June 25, 2026
- Hearing scheduled for 10/28/2025 from 01:00 PM-05:00 PM in B-2
- Referred to the committee on Revenue
- House concurred
Sponsors
- Jason M. Lewis (D) · sponsor
- Rebecca L. Rausch
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when S 2035 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track S 2035 freeOr ask your AI assistant about S 2035 directly:
Add to Claude, ChatGPT or Cursor